BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

551 related articles for article (PubMed ID: 28821272)

  • 1. Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia.
    Wei G; Wang J; Huang H; Zhao Y
    J Hematol Oncol; 2017 Aug; 10(1):150. PubMed ID: 28821272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoclonal antibodies and immune therapies for adult precursor B-acute lymphoblastic leukemia.
    Sikaria S; Aldoss I; Akhtari M
    Immunol Lett; 2016 Apr; 172():113-23. PubMed ID: 26921100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New monoclonal antibodies for the treatment of acute lymphoblastic leukemia.
    Farhadfar N; Litzow MR
    Leuk Res; 2016 Oct; 49():13-21. PubMed ID: 27521873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The ABCs of Immunotherapy for Adult Patients With B-Cell Acute Lymphoblastic Leukemia.
    Horvat TZ; Seddon AN; Ogunniyi A; King AC; Buie LW; Daley RJ
    Ann Pharmacother; 2018 Mar; 52(3):268-276. PubMed ID: 29025266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging biological therapies to treat acute lymphoblastic leukemia.
    Huguet F; Tavitian S
    Expert Opin Emerg Drugs; 2017 Mar; 22(1):107-121. PubMed ID: 27820973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Novel bispecific T-cell engager (BiTE) targeting CD22 and CD3 has both in vitro and in vivo activity and synergizes with blinatumomab in an acute lymphoblastic leukemia (ALL) tumor model.
    Meckler JF; Levis DJ; Vang DP; Tuscano JM
    Cancer Immunol Immunother; 2023 Sep; 72(9):2939-2948. PubMed ID: 37247022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel antibody therapy in acute lymphoblastic leukemia.
    Kochuparambil ST; Litzow MR
    Curr Hematol Malig Rep; 2014 Jun; 9(2):165-73. PubMed ID: 24623281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-based therapies in B-cell lineage acute lymphoblastic leukaemia.
    Le Jeune C; Thomas X
    Eur J Haematol; 2015 Feb; 94(2):99-108. PubMed ID: 24981395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy approaches to treat adult acute lymphoblastic leukemia.
    Maino E; Bonifacio M; Scattolin AM; Bassan R
    Expert Rev Hematol; 2016 Jun; 9(6):563-77. PubMed ID: 27011303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing the efficacy of salvage regimens for relapsed/refractory B-cell acute lymphoblastic leukaemia: a systematic review and network meta-analysis.
    Cao HY; Wan CL; Xue SL
    Ann Hematol; 2023 Jan; 102(1):155-165. PubMed ID: 36394582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should immunologic strategies be incorporated into frontline ALL therapy?
    Rank CU; Stock W
    Best Pract Res Clin Haematol; 2018 Dec; 31(4):367-372. PubMed ID: 30466749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [CD19 antigen loss after treatment of Bispecific T-cell Engager and effective response to salvage bispecific CAR-T therapy in B cell acute lymphoblastic leukemia: a case report and literature review].
    Fu XH; Wang Y; Wang HJ; Wei SN; Xu YX; Xing HY; Tang KJ; Tian Z; Rao Q; Wang JX; Wang M
    Zhonghua Xue Ye Xue Za Zhi; 2020 Apr; 41(4):282-286. PubMed ID: 32447930
    [No Abstract]   [Full Text] [Related]  

  • 13. Novel antibody-based therapies for acute lymphoblastic leukemia.
    Hoelzer D
    Hematology Am Soc Hematol Educ Program; 2011; 2011():243-9. PubMed ID: 22160041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted therapy with monoclonal antibodies in acute lymphoblastic leukemia.
    Hoelzer D
    Curr Opin Oncol; 2013 Nov; 25(6):701-6. PubMed ID: 24097105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors.
    Aldoss I; Bargou RC; Nagorsen D; Friberg GR; Baeuerle PA; Forman SJ
    Leukemia; 2017 Apr; 31(4):777-787. PubMed ID: 28028314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigational immunotherapy targeting CD19 for the treatment of acute lymphoblastic leukemia.
    Viardot A; Sala E
    Expert Opin Investig Drugs; 2021 Jul; 30(7):773-784. PubMed ID: 33998346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia.
    DasGupta RK; Marini BL; Rudoni J; Perissinotti AJ
    J Oncol Pharm Pract; 2018 Sep; 24(6):453-467. PubMed ID: 28583018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Humoral and cellular immunotherapy in ALL in children, adolescents, and young adults.
    Hochberg J; El-Mallawany NK; Cairo MS
    Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S6-13. PubMed ID: 25486958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging role of immunotherapy in precursor B-cell acute lymphoblastic leukemia.
    Valecha GK; Ibrahim U; Ghanem S; Asti D; Atallah JP; Terjanian T
    Expert Rev Hematol; 2017 Sep; 10(9):783-799. PubMed ID: 28666090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in the treatment of acute lymphoblastic leukemia.
    Rafei H; Kantarjian HM; Jabbour EJ
    Leuk Lymphoma; 2019 Nov; 60(11):2606-2621. PubMed ID: 31092071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.